2024-512945-18-00
Completed
Phase 3
A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Apellis Pharmaceuticals Inc.41 sites in 7 countries206 target enrollmentStarted: September 16, 2024Last updated:
Overview
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Apellis Pharmaceuticals Inc.
- Enrollment
- 206
- Locations
- 41
- Primary Endpoint
- Incidence and severity of ocular and systemic Aes
Overview
Brief Summary
To evaluate the long-term safety of IVT-injected pegcetacoplan
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Ocular-specific inclusion criteria apply to the study eye.
- •Participated in APL2-103 (NCT03777332) or completed the treatment at month 24 of either APL2-303 (Derby, NCT03525613) or APL2-304 (Oaks, NCT03525600). Specifically, for the APL2-303 and APL2-304 studies, the following criterion also applies: a. Participants who did not permanently discontinue treatment but missed the month 24 visit are also eligible to participate in this extension study; however, to be eligible, these participants must be screened within 60 days from the last day of the expected month 24 visit window for the antecedent study.
- •Clarity of ocular media, adequate pupillary dilation, and fixation to permit the collection of good quality images as determined by the investigator. Inclusion criterion #2 applies to the fellow eye.
- •Female participants must be: a. Women of nonchildbearing potential, or b. Women of childbearing potential (WOCBP), defined as any women who have experienced menarche and who are not permanently sterile or postmenopausal, must have a negative serum pregnancy test at screening and must agree to use protocol defined methods of contraception for the duration of the study and 90 days after their last dose of pegcetacoplan, and refrain from breastfeeding for the duration of the study.
- •Males with female partners of childbearing potential must agree to use protocol defined methods of contraception and agree to refrain from donating sperm for the duration of the study and for 90 days after their last dose of pegcetacoplan.
- •Willing and able to give informed consent and to comply with the study procedures and assessments.
Exclusion Criteria
- •Ocular-specific exclusion criteria apply to the study eye.
- •Participants who permanently discontinued the study drug prior to month 24 in the APL2-304 or APL2-304 studies and only for safety assessments. Temporary pause of the study drug is not exclusionary.
- •Presence of an active ocular disease that, in the opinion of the investigator, compromises or confounds visual function, including, but not limited to, macular hole or other macular diseases (eg, clinically significant epiretinal membrane). Benign conditions in the opinion of the investigator such as peripheral retinal dystrophy are not exclusionary. Exclusion criteria 2 and 3 apply to the fellow eye.
- •Any contraindication to IVT injection including current ocular or periocular infection. Exclusion criteria 2 and 3 apply to the fellow eye.
- •Medical or psychiatric condition that, in the opinion of the investigator, is clinically significant and not suitable for study participation or make consistent follow-up over the 36-month treatment period unlikely.
- •Known hypersensitivity to fluorescein sodium for injection or hypersensitivity to pegcetacoplan or any of the excipients in pegcetacoplan solution.
- •Pregnancy, breastfeeding, or positive pregnancy test.
Outcomes
Primary Outcomes
Incidence and severity of ocular and systemic Aes
Incidence and severity of ocular and systemic Aes
Secondary Outcomes
- 1.The total area of GA lesion(s) in the study eye (in mm2) as assessed by fundus autofluorescence (FAF)
- 2.The rate of GA lesion growth in the study eye as assessed by fundus autofluorescence (FAF)
- 3.NL-BCVA score (study eye) as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) chart
- 4. LL-BCVA score (study eye) as assessed by ETDRS chart
- 5. Monocular maximum reading speed (study eye) corrected for number of words read incorrectly as assessed by Minnesota Reading (MNRead) charts or Radner charts
- 6. Binocular maximum reading speed, corrected for number of words read incorrectly, as assessed by MNRead charts or Radner charts
- 7.The number of absolute scotomatous points (study eye) assessed by mesopic microperimetry (selected participants [those who had the assessment performed in the antecedent study] only)
- 8. Macular sensitivity (study eye) as assessed by mesopic microperimetry (selected participants [those who had the assessment performed in the antecedent study] only)
- 9. Change in additional microperimetry parameters in the study eye (eg, 95% bivariate contour ellipse area [BCEA], number of points with a clinically significant decrease in mean sensitivity)
- 10.Mean FRI Index score
- 11. NEI VFQ25 and NEI VFQ-39 (at select sites) composite score, near activity subscale score, distance activity subscale score, and NEI VFQ-25 driving subscale score
Investigators
Clin. Development and Med. Affairs
Scientific
Apellis Pharmaceuticals Inc.
Study Sites (41)
Loading locations...
Similar Trials
Active, not recruiting
Phase 3
A study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALE)2023-504625-39-00Apellis Pharmaceuticals Inc.66
Completed
Phase 3
Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease2024-511553-22-00Celgene International II SARL462
Not yet recruiting
Phase 3
Vedolizumab Subcutaneous Long-term Open-label Extension Study in Pediatric Subjects2023-508804-39-00Takeda Development Center Americas Inc.32
Recruiting
Phase 3
An Open-Label Extension Study of Fazirsiran2023-503497-21-00Takeda Development Center Americas Inc.18
Enrolling By Invitation
Not Applicable
Persona SoluTion PPS Femur PMCFNCT07286513Zimmer Biomet200